Should LDH Be Ordered in the Workup of Monoclonal Gammopathy?
Yes, lactate dehydrogenase (LDH) should be measured as part of the standard investigative workup for monoclonal gammopathy, particularly when multiple myeloma is suspected or confirmed. 1
Guideline-Based Recommendations
The International Myeloma Working Group (IMWG) explicitly includes serum β2-microglobulin and lactate dehydrogenase in their consensus recommendations for laboratory tests in multiple myeloma workup. 1 This recommendation appears in Table 2 of their standardized diagnostic panel, positioning LDH as a core component of the initial assessment rather than an optional test.
When LDH Testing Is Indicated
For Suspected or Confirmed Multiple Myeloma
- LDH should be measured at diagnosis in all patients with suspected multiple myeloma as part of the standard laboratory panel. 1
- While not required for diagnosis itself, LDH provides critical prognostic information and helps assess tumor burden. 1
For Intermediate and High-Risk MGUS
- In patients with MGUS showing concerning features (M-protein >15 g/L, IgA or IgM type, or abnormal free light chain ratio), LDH should be determined if there is evidence of multiple myeloma or Waldenström's macroglobulinemia. 2
- LDH testing is particularly important when bone marrow examination reveals findings suggestive of progression beyond MGUS. 2
For Low-Risk MGUS
- Routine LDH testing is not indicated for low-risk MGUS (M-protein <15 g/L, IgG type, normal FLC ratio) in the absence of clinical symptoms. 2
- These patients can be monitored with serum protein electrophoresis alone unless symptoms develop. 2
Clinical Significance and Prognostic Value
Mortality and Survival Impact
- Elevated LDH is independently associated with significantly worse overall survival, even in the era of novel agents. 3, 4
- Patients with high LDH (>300 U/L) have a median survival of only 15 months compared to 44 months for those with normal LDH. 3
- High LDH identifies very-high-risk multiple myeloma patients with median survival of 21 months despite novel agent therapy. 4
Prognostic Value Beyond ISS Staging
- LDH adds independent prognostic value to the International Staging System, stratifying patients within each ISS category. 3
- Among ISS-1 patients, high LDH reduces median survival from 76 to 22 months. 3
- Multivariate analysis confirms LDH as an independent predictor of survival (P < 0.001) alongside ISS, performance status, age, and platelet counts. 3
Disease Biology Indicators
- Elevated LDH suggests occult extraosseous disease and high tumor burden. 5
- High LDH is associated with plasma cell leukemia, lymphoma-like features (43% of cases), and plasma cell hypodiploidy (17%). 5
- Only 20% of patients with elevated LDH respond to chemotherapy compared to 57% response rate in those with normal LDH. 5
Common Pitfalls and Clinical Caveats
Interpretation Considerations
- Abnormally high LDH during follow-up should prompt immediate evaluation for disease progression, including bone marrow examination and assessment for extramedullary plasmacytomas. 6
- LDH can increase dramatically (up to 27-fold) with disease progression and development of extramedullary disease. 6
Risk Stratification
- Elevated LDH at first relapse is a key prognostic factor (P = 0.001) and should trigger re-evaluation of treatment strategy. 7
- At relapse, high LDH correlates with higher β2-microglobulin, lower albumin, lower platelets, and higher rates of extramedullary disease. 7
Treatment Resistance
- High LDH predicts drug resistance with an odds ratio of 0.25 for treatment response (P = 0.001). 5
- These patients should be considered for early intensive treatment or clinical trial enrollment. 5
Practical Algorithm
Initial Workup:
- Measure LDH in all patients with suspected or confirmed multiple myeloma 1
- Measure LDH in intermediate/high-risk MGUS when bone marrow examination is performed 2
- Defer LDH in low-risk MGUS without symptoms 2
Monitoring: